SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

SEPN

Septerna, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed7d 5h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor upcoming Phase 1 data for SEP-479 and SEP-204 in Q1 2027 as key catalysts. The revenue miss and wider loss may pressure the stock near-term, but the strong cash runway and pipeline milestones provide a longer-term focus.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

SEPN drug pipeline →

SEP-479

● Neutral Named in this press release
Impact
Phase
Phase 1
Time to market
If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$52.34
T+0 close · Nov 9, 2026 · via day close
Latest settled
−7.22%
T+1 · $48.56
Vs SPY
−8.54%
α at T+1
Next horizon
T+5
in 9h
  1. T+0 · Nov 10 $52.34entry
  2. T+1 · 6d ago −7.22%α −8.54% · $48.56
  3. T+4 · todayOpen
  4. T+5 · in 9h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna reported Q3 2026 revenue of $18.9M (below consensus $20.8M) and a GAAP EPS loss of $0.57 (wider than the consensus loss of $0.40). The company highlighted pipeline progress for SEP-479 and SEP-204, with Phase 1 data expected in Q1 2027, and maintains a cash runway into mid-2029.

Key Financial Metrics

EPS
−$0.57
est −$0.40 · -42.5%
Revenue
$18.9M
est $20.8M · -9.2% · -12.2% YoY
Rating
miss

Key Facts

  • Q3 2026 revenue $18.9M vs consensus $20.8M and vs $21.5M in Q3 2025
  • GAAP diluted EPS -$0.57 vs consensus -$0.40 and vs +$0.18 in Q3 2025
  • Net loss $26.6M vs net income $8.2M in Q3 2025
  • Cash position $565.2M, expected to fund operations into mid-2029
  • Phase 1 data for SEP-479 (PTH1R agonist) expected Q1 2027
  • SEP-204 (TSHR NAM) Phase 1 trial planned for Q1 2027
  • Novo collaboration milestones achieved $13M to date

Financial Impact

Revenue miss of ~$1.9M (9% below consensus) and EPS miss of $0.17 (42.5% below consensus)

revenueepsnet loss

Risk Factors

  • Revenue decline YoY and below consensus
  • Wider net loss compared to prior year
  • Clinical-stage biotech with no approved products; pipeline execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398924

Track record

25 reports on SEPN

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
  2. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  3. Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
  5. Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
  6. Nov 9, 20267d ago Press Release Bearish 5/10 Viewing Entry $52.34 Now $41.67 +20.39% settles Nov 17
  7. Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
  9. Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
  10. Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (11h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026